Pharmacopeia, Neurocrine expand drug discovery, development collaboration

By Elaine Rigoli

Tampa, Fla., March 15 - Pharmacopeia announced Wednesday it has joined forces with Neurocrine Biosciences Inc. to expand the scope of their collaboration to include an additional disease target against which Pharmacopeia is expected to produce candidates for Neurocrine.

"We are very excited about our collaboration with Neurocrine as it enables us to apply our proven drug discovery and development platform to central nervous system and metabolic disease targets," Les Browne, president and chief executive officer of Pharmacopeia, said in a statement.

"We have enjoyed a productive collaboration with Neurocrine to date and look forward to continuing our success by delivering high-value candidates against this latest disease target."

In 2003, Pharmacopeia and Neurocrine established their existing collaboration with the goal of producing compounds against multiple disease targets that Neurocrine would advance into development and onto the market, according to a news release.

Since the collaboration began, Pharmacopeia said it has delivered to Neurocrine a number of compounds against selected disease targets.

Based on the terms of the collaboration, Pharmacopeia is entitled to receive milestone payments from Neurocrine if collaboration programs progress into and through clinical development, the release said.

Additionally, if therapeutic products are marketed based on compounds derived from the collaboration, Pharmacopeia will be entitled to receive royalties on sales.

San Diego-based Neurocrine is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders.

Pharmacopeia creates and delivers novel therapeutics to address significant medical needs. The company is based in Princeton, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.